PRELIMINARY SCIENTIFIC SESSIONS

FRIDAY, SEPTEMBER 12, 2014

7:00 am REGISTRATION/CONTINENTAL BREAKFAST/EXHIBITS
7:55 WELCOME: Julia Haller, MD, President

SURGERY I
PRESIDING OFFICER: Donald D’Amico, MD
MODERATOR: Maria Berrocal, MD

8:00 am Characteristics and Outcomes of Sequential Rhegmatogenous Retina Detachments
Harpreet Walia, MD

8:05 Visual and Anatomic Outcomes of Epiretinal Membrane Peeling after Previous Complex Retinal Detachment Surgery
Christina Weng, MD

8:10 Vitrectomy Techniques with 27g Instrumentation in Complex Detachments
Maria Berrocal, MD

8:15 Dual Port Cutter Vitrectomy for Dense Vitreous Hemorrhage: Preliminary Study
Luiz Lima, MD

8:20 Evaluating Small Gauge Instrumentation from a New “Intraocular” Perspective
Kirk Packo, MD

8:25 Collaborative Multi-Center Study of Macular Holes: The European Vitreo-Retinal Society Macular Hole Study
Ron Adelman, MD

8:30 Results and Complications of Vitrectomy for Pseudohole/Lamellar Macular Holes
John Thompson, MD

8:35 Anterior Chamber Migration of the Dexamethasone Implant (Ozurdex) May Result in Corneal Decompensation
Rahul Khurana, MD

8:40 Fellow Eyes of Giant Retina Tears: Effectiveness of Prophylactic Laser Treatment Compared to Untreated Fellow Eyes
Guido Ripandelli, MD

8:45 Discussion

8:49 Small Incision Vitreoretinal Surgery Without Scleral Depression Shaving of Vitreous Base for Rhegmatogenous Retinal Detachment
Homayoun Tabandeh, MD

8:55 Discussion

8:58 Para Plana Vitrectomy-Scleral Buckle versus Pars Plana Vitrectomy Alone for Patients with Rhegmatogenous Retinal Detachment at High Risk of Proliferative Vitreoretinopathy
Philip Storey, MD

9:04 Discussion

9:07 The DISCOVER Study: Prospective Analysis of Real-time Intraoperative OCT During Vitreoretinal Surgery Utilizing a Microscope-Integrated Prototype with a Heads-up Display Surgeon Feedback System
Justis Ehlers, MD

CONTINUES ON NEXT PAGE
9:13 am Discussion
9:16 Sustained Release Dexamethasone Intravitreal Implant (DEX) for Persistent Macular Edema (ME) After Vitrectomy (PPV) for Epiretinal Membrane (ERM)
Caroline Baumal, MD
9:22 Discussion
9:25 Vitrectomy After Ocriplasmin for Vitreomacular Adhesion or Macular Hole (VAVOOM) Study
Margaret Greven, MD
9:31 Discussion
9:34 Subretinal Air Displacement of Submacular Hemorrhage: Initial Experience
Michael Ober, MD
9:40 Discussion
9:43 One-year Outcomes of Eyes Treated with Sutureless Scleral Fixation Technique for Intraocular Lens Placement or Rescue
Jonathan Prenner, MD
9:49 Discussion
9:52 Advances in Vitreoretinal Evaluation and Surgery with Permanent Keratoprosthesis
Donald D’Amico, MD
9:58 Discussion

PRACTICE MANAGEMENT
10:01 Quality Measures Within a Group Retina Practice—Cultural Shift and Clinical Outcomes
Brian Joondeph, MD
10:06 – 10:36 REFRESHMENT BREAK/EXHIBITS

INFLAMMATION
PRESIDING OFFICER: Bernard Doft, MD
MODERATOR: Sunir Garg, MD
10:36 Analysis of Birdshot Chorioretinopathy Abnormalities using SD-OCT and Fundus Autofluorescence Imaging
David Sarraf, MD
10:41 Torque Teno Virus is Associated with Culture-negative Endophthalmitis
Sunir Garg, MD
10:47 Discussion
10:50 The Current Face of Endophthalmitis: 107 Consecutive Cases
Bernard Doft, MD
10:56 Discussion
10:59 FELLOWSHIP RESEARCH AWARD PRESENTATION
INTRODUCTION: David Zacks, MD
Optical Coherence Tomography Drusen Volume and Retinal Pigment Epithelium Abnormal Thinning Volume Predict 2-Year Progression of Age-Related Macular Degeneration
Francisco Folgar, MD
CONTINUES ON NEXT PAGE
11:11 am

8th ANNUAL J. DONALD M. GASS AWARD
Alexander Brucker, MD

11:45

LUNCH

AGE-RELATED MACULAR DEGENERATION - I

PRESIDING OFFICER: Charles Barr, MD
MODERATOR: Susan Bressler, MD

12:45 pm
A Value-based Medicine\textsuperscript{®} Analysis of Genetic Testing for Neovascular Age-Related Macular Degeneration. Patient Value Gain and Financial Return-on-Investment
Gary Brown, MD

12:51 Discussion

12:54 Detection Rate of New CNV in Eyes with AMD and Visits Promoted by Home Monitoring Device, Symptoms and Standard Care
Susan Bressler, MD

1:00 Discussion

1:03 Comparison of Distance and Near Vision in the Better-seeing Eye versus Both Eyes in Neovascular Age-Related Macular Degeneration
Neil Bressler, MD

1:09 Discussion

1:12 Concentration of Vitamins C, Vitamin E, Zinc and Copper in Dietary Supplements
Charles Barr, MD

1:18 Discussion

1:21 Combined Complement Factor H (CFH) and Age-Related Maculopathy Susceptibility 2 (ARMS2) Risk Predicts Response to AMD Nutritional Prophylaxis: A New Analysis of AREDS Data
Carl Awh, MD

1:27 Discussion

1:30 Preliminary Results of Phase I Study with AAV2-sFLT01 as Gene Therapy for Treatment of Exudative AMD
Jeffrey Heier, MD

1:36 Discussion

1:39 Outer Retinal Tubulation as a Predictor of the Growth Rate of Geographic Atrophy in Age-Related Macular Degeneration
Srinivas Sadda, MD

1:45 Discussion

1:48 – 2:18 REFRESHMENT BREAK

AGE-RELATED MACULAR DEGENERATION I CONTINUED

PRESIDING OFFICER: Jennifer Kang-Mieler, PhD
MODERATOR: James Vander, MD

2:18 Baseline Retinal Pigment Epithelial Elevation (RPEE) Size and Intra-Retinal Fluid (IRF) Status Effect on Visual Acuity (VA) Outcomes in the VIEW 1 and VIEW 2
Chirag Shah, MD

CONTINUES ON NEXT PAGE
Dennis Han, MD

2:28  Cost Accounting and Prescribing Patterns of Bevacizumab Before and After Enforcement of Patient-Specific Prescription Rules
Raymond Sjaarda, MD

2:33  Influence of Vitreomacular Interface on Anti-VEGF Therapy using Treat and Extend Treatment Protocol for Neovascular Age-Related Macular Degeneration
Samuel Houston, III, MD

2:39  Discussion

2:42  A Systemic Review (Meta-Analysis) of PRN versus Treat and Extend Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Regiments for Neovascular Age-Related Macular Degeneration
David Chin Yee, MD

2:48  Discussion

2:51  Long-Term Treatment Outcomes for Neovascular Age-Related Macular Degeneration using a “Treat and Extend” Regimen
Nadim Rayess, MD

2:57  Discussion

3:00  Bioactive Lysophospholipids Generated by Hepatic Lipase Degradation of Lipoproteins Activate Complement via the Classical Pathway
Gaetano Barile, MD

3:06  Discussion

3:09  Controlled Extended Release of Ranibizumab from Novel Ocular Drug Delivery System
Jennifer Kang-Mieler, PhD

3:15  Discussion

3:18  Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)
Sumit Sharma, MD

3:24  Discussion

3:27  Morphological Biomarkers Associated with Visual Acuity Gain and Loss in Eyes with Neovascular Age-Related Macular Degeneration Treated with Dual Antagonism of PDGF (Fovista 1.5 mg™)/VEGF (Lucentis® 0.5mg)
Glenn Jaffe, MD

3:33  Discussion

3:36  ADJOURN
7:00 am  REGISTRATION/CONTINENTAL BREAKFAST/EXHIBITS

AGE-RELATED MACULAR DEGENERATION - II
PRESIDING OFFICER: Mark Johnson, MD
MODERATOR: Mark Blumenkranz, MD

8:00 am  Evidence that Macular Degeneration is not Simply a Disease of the Posterior Pole
Thomas Friberg, MD

8:05  Diagnosis of Cognitive Impairment and Alzheimer’s Disease Using Integrated Assessments of Retina Structure and Function
Felix Sabates, MD

8:10  Incidence of Sustained Ocular Hypertension Using Prepackaged versus Freshly-prepared Intravitreal Bevacizumab Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Jason Hsu, MD

8:15  One-year Results of a Phase 1 Study of the Safety and Tolerability of Combination Therapy Using Sustained Release Intravitreal Triamcinolone Acetonide and Ranibizumab for Subfoveal Neovascular Age-Related Macular Degeneration
Jennifer Lim, MD

8:20  Systemic Review of Safety Across the Phase 2 and 3 Clinical Trials of Intravitreal Aflibercept Injection
David Boyer, MD

8:26  Discussion

8:29  Intravitreal Aflibercept Decreases the Volume of Vascularized PEDs Better than Frequent Retreatment with Intravitreal Bevacizumab or Ranibizumab
Philip Rosenfeld, MD

8:35  Discussion

8:38  One-year Results from the ROLL Trial: Aflibercept for Patients with Recalcitrant PEDs Related to Wet Age-Related Macular Degeneration
Brandon Busbee, MD

8:44  Discussion

8:47  Type 3 Neovascularization: Evolution, Association with Pigment Epithelial Detachment, and Response to Therapy as Revealed by Spectral-Domain Optical Coherence Tomography
Aaron Nagiel, MD

8:53  Discussion

8:56  Gap Between BCVA and Low-luminance VA at Baseline Predicts Treatment Response to Ranibizumab at Year 2 of the HARBOR Study
Ronald Frenkel, MD

9:02  Discussion
OTHER MACULAR

PRESIDENT OFFICER: Jennifer Lim, MD
MODERATOR: Shlomit Schaal, MD

9:05 am Ocular Coloboma Classification and Examination of Ultrasound as a Supplementary Measure of Prognosis
Nina Berrocal, MD

9:10 Acute Macular Neuroretinopathy Following Non-Ocular Trauma: A New Proposal Regarding Pathogenesis
Mark Johnson, MD

9:16 Discussion

9:19 Validation of the Accuracy and Precision of Out-of-Office Testing for Retinal Disease: New Developments and Clinico-Pathologic Correlations
Mark Blumenkranz, MD

9:25 Discussion

9:28 Anatomic and Functional Outcomes of Symptomatic Vitreo-Foveal Adhesion. A Pilot Study from the Pan American Collaborative Retina Study Group
Lihteh Wu, MD

9:34 Discussion

9:37 Vitreomacular Traction: Clinical Course and Outcomes Managed by Initial Observation
Harry Flynn, MD

9:43 Discussion

9:46 Variations and Racial Differences in the Pattern of Hydroxychloroquine Retinopathy
Michael Marmor, MD

9:52 Discussion

9:55 Choroidal Flecks in Stargardt's Disease Shown by High Definition Optical Coherence Tomography Imaging Correlate with Disease Severity
Shlomit Schaal, MD

10:01 Discussion

10:04 –10:34 REFRESHMENT BREAK/EXHIBITS

10:34 RAYMOND R. MARGHERIO AWARD PRESENTATION
INTRODUCTION: David Zacks, MD
Iron Rescue of Deferoxamine Toxicity in Human RPE Cells
John Miller, MD

10:46 RETINA RESEARCH AWARD OF MERIT – CHARLES L. SCHEPENS LECTURE
INTRODUCTION: Julia Haller, MD
Development of Treatments for Retinal/Choroidal Vascular Diseases
Peter Campochiaro, MD

11:20 INTRODUCTION OF GUESTS OF HONOR
INTRODUCTION: Julia Haller, MD
Ralph Eagle, MD
Harry Flynn, MD

11:40 ANNUAL BUSINESS MEETING

12:15 – 1:00 pm LUNCH

CONTINUES ON NEXT PAGE
1:00 – 1:30
DEDICATED POSTER SESSION/DESSERTS – MEADE/GRANT ROOMS

TUMORS
PRESIDING OFFICER: Jerry Shields, MD
MODERATOR: Ivana Kim, MD

1:30 pm
Initial Treatment and Outcomes of Unilateral and Bilateral Retinoblastoma in a Midwestern University Pediatric Oncology Center 1999 – 2013
James Augsburger, MD

1:35
Clinical Characteristics of Uveal Melanoma in Patients with Germline BAP1 Mutations
Mrinali Patel, MD

1:40
Ranibizumab in Combination with Proton Beam Irradiation for Choroidal Melanoma: Interim Results
Ivana Kim, MD

1:45
Treatment of Radiation-Induced Maculopathy
William Mieler, MD

1:50
Retinal Metastasis from Systemic Cancer in Eight Cases
Carol Shields, MD

1:56
Discussion

1:59
Tumors of the Non-Pigmented Epithelium of the Ciliary Body. The Zimmerman Classification Revisited
Jerry Shields, MD

2:05
Discussion

2:08
Cytological Characteristics of Uveal Melanoma
Carlos Medina, MD

2:14
Discussion

2:17
Micro-incisional Vitrectomy Surgery (MIVS) Enables Laser Tumor Ablation and Fine Needle Aspiration Biopsy (FNAB) Potentially Avoiding Radiotherapy in Small Uveal Malignant Melanoma
Timothy Murray, MD

2:23
Discussion

2:26
The American Brachytherapy Society (ABS) Consensus Guidelines for Plaque Brachytherapy of Uveal Melanoma and Retinoblastoma
Paul Finger, MD

2:32
Discussion

2:35
Ruthenium Eye Plaques for Uveal Melanoma: Long-Term Clinical Outcome
Arun Singh, MD

2:41
Discussion

2:44
Long-Term Visual Prognosis After Proton Irradiation of Uveal Melanomas in Patients at High Risk of Vision Loss
Evangelos Gragoudas, MD

2:50
Discussion

CONTINUES ON NEXT PAGE
### GENETICS

**Presiding Officer:** Kimberly Drenser, MD  
**Moderator:** Steve Schwartz, MD

2:53 pm  
Genotype-Phenotype Correlation of Patients with Wnt Pathway Mutations Associated with Familial Exudative Vitreoretinopathy: A Basis for Genetically Tailored Management  
Kimberly Drenser, MD

2:58  
Retinal Nerve Fiber Dysfunction in Retinal Degeneration  
John Heckenlively, MD

3:03  
Comparison of Circulating microRNAs in Aqueous and Vitreous as Putative Novel Diagnostic Biomarkers for Diabetic Retinopathy  
Lawrence Morse, MD

3:08  
Vision Improvement After Retreatment with an Oral Synthetic cis-Retinoid (QLT091001) in Subjects with Inherited Retinal Disease Caused by Mutations in RPE65 or LRAT  
Hendrik Scholl, MD

3:14  
Discussion

3:17  
Safety and Technical Aspects of Subretinal Injection for Delivery of Cell and Gene Therapy  
Steven Schwartz, MD

3:23  
Discussion

3:26 – 3:56  
**Refreshment Break/Exhibits**

### IMAGING

**Presiding Officer:** Judy Kim, MD  
**Moderator:** Bailey Freund, MD

3:56  
Ultra-Widefield Imaging with Autofluorescence and Indocyanine Green Angiography in Central Serous Chorioretinopathy  
Claudine Pang, MD

4:01  
Inner Retina and Vascular Imaging in Macular Telangiectasis Using Adaptive Optics  
Judy Kim, MD

4:06  
Outer Retinal Tubulation in Advanced Age-Related Macular Degeneration: Optical Coherence Tomographic Findings Correlate with Histology  
Bailey Freund, MD

4:12  
Discussion

4:15  
Feasibility of Dynamic Optical Coherence Tomography and Infrared Imaging  
Edwin Ryan, MD

4:21  
Discussion

4:24  
Quantitative Dynamics of Retina Microvascular Disease Revealed by Adaptive Optics Scanning Light Ophthalmoscopy  
Richard Rosen, MD

4:30  
Discussion

4:33  
Rapid Grading of Fundus Photos for Diabetic Retinopathy Using Crowdsourcing: External Validation  
Christopher Brady, MD

4:39  
Discussion

CONTINUES ON NEXT PAGE
PEDIATRICS

PRESIDING OFFICER: Antonio Capone, MD
MODERATOR: Mary Elizabeth Hartnett, MD

4:42 pm
Selective Immediate Sequential Bilateral Pediatric Vitreoretinal Surgery
Antonio Capone, Jr. MD

4:47
Identification of the Fovea and Diagnosis of Zone by Fluorescein Angiography in Patients with the Diagnosis of Retinopathy of Prematurity (ROP)
R. V. Paul Chan, MD

4:52
Vascular Endothelial Growth Factor (VEGF) Receptor Activates and Interacts With the Erythropoietin Receptor to Cause Pathologic Angiogenesis
Mary Elizabeth Hartnett, MD

4:58
Discussion

5:01
Newborn Eye Screen Testing: Evaluation of Retinal Hemorrhage, Localization and Timing of Resolution
Darius Moshfeghi, MD

5:07
Discussion

5:10
ADJOURN

SUNDAY, SEPTEMBER 14

7:30 am
REGISTRATION/CONTINENTAL BREAKFAST/EXHIBITS

OTHER MACULA - II

PRESIDING OFFICER: Nancy Holekamp, MD
MODERATOR: Franco Recchia, MD

8:00
Canadian Assessment of Real-world Efficacy and Safety of Dexamethasone Intravitreal Implant (0.7 mg) in Patients with Macular Edema
David Maberly, MD

8:05
A Pilot Study of Intravitreal Aflibercept for the Treatment of Chronic Central Serous Chorioretinopathy: The CONTAIN Study
John Pitcher, MD

8:11
Discussion

8:14
Mineralocorticoid Antagonist in the Treatment of Central Serous Retinopathy
Kapil Kapoor, MD

8:20
Discussion

VASCULAR

8:23
Aflibercept for Recalcitrant Central Retinal Vein Occlusion-Associated Macular Edema Despite Prior Anti-VEGF Therapy (The ARChiMEDES Trial)
Franco Recchia, MD

8:28
Effect of Aflibercept on Refractory Macular Edema Associated with Central Retinal Vein Occlusion
Michael Cohen, MD
8:33 am REVOLUTIONARY: A Pilot Trial of Combination Peripheral Scatter Laser and Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
Ivan Suner

8:38 Real World Vision Outcomes in RVO Treated with Anti-VEGF Injections – An Analysis of EMR Data from a Large Integrated US Health System
Nancy Holekamp, MD

8:43 Two or More Dexamethasone Intravitreal Implants Used Alone Versus with Adjunctive Therapy in Patients with Macular Edema Secondary to Retinal Vein Occlusion
Daniel Roth, MD

8:49 Discussion

8:52 Long-Term Effects of Combination Therapy Using Anti-Vascular Endothelial Growth Factor Agents (Anti-VEGF) and Dexamethasone Intravitreal Implant (Ozurdex) for Retinal Vein Occlusions (RVO)
Michael Singer, MD

8:58 Discussion

9:01 52-Week Results of the VIBRANT Study on Intravitreal Aflibercept Injection in Macular Edema Secondary to Branch Retinal Vein Occlusion
Julia Haller, MD

9:07 Discussion

9:10 Multimodal Imaging Analysis of Deep Capillary Plexus Ischemia in Central Retinal Vein Occlusion
Ehsan Rahimy, MD

9:06 Discussion

9:19 Early Visual Acuity Improvement in RVO Patients Treated with Ranibizumab in the SHORE Study
Lloyd Clark, MD

9:25 Discussion

9:28 – 9:58 REFRESHMENT BREAK/EXHIBITS

DIABETES
PRESIDING OFFICER: Allen Ho, MD
MODERATOR: Ingrid Scott, MD

9:58 Real World Vision Outcomes of DME Treated with Anti-VEGF Injections—An Analysis of EMR Data From a Large Integrated US Health System
Szilard Kiss, MD

10:03 Automated Identification and Quantification of Fluorescein Leakage in Patients with Diabetic Macular Edema
Thiran Jayasundera, MD

10:08 Intravitreal Aflibercept for Diabetic Macular Edema: 24-Month Results from VISTA-DME and VIVID-DME
David Brown, MD

10:14 Discussion

10:17 Evaluation of Rescue Treatment with Intravitreal Aflibercept Injection (IAI) in Patients with Diabetic Macular Edema (DME) Receiving Laser in the VISTA-DME and VIVID-DME Studies
Dennis Marcus, MD
10:23 am Discussion

10:26 Intravitreal Aflibercept in the VISTA-DME and VIVID-DME Studies: Subgroup Analysis by Baseline Demographics and Systemic Disease Characteristics
Charles Wykoff, MD

10:32 Discussion

10:35 Initial Choroidal Thickness as a Predictor for Short-term Response to Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Diabetic Macular Edema
Nika Bagheri, MD

10:41 Discussion

10:44 Anti-VEGF Therapy for Diabetic Macular Edema (DME): Comparison of Year 1 Results from Prospective, Randomized, Controlled Clinical Trials
Allen Ho, MD

10:50 Discussion

10:53 Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results
Christina Flaxel, MD

10:59 Discussion

11:02 Open-Label Extension of the Phase III RIDE and RISE Trials—Characteristics of DME Patients Associated with Treatment Frequency
Carl Regillo, MD

11:08 Discussion

11:11 Repeated Ranibizumab Injections and Incidence of Sustained IOP Elevations or Initiation of Ocular Hypotensive Treatment in Eyes with Diabetic Macular Edema
Seema Garg, MD

11:17 Discussion

11:20 Long-term Efficacy and Safety of Dexamethasone Intravitreal Implant for Treatment of Diabetic Macular Edema in Phakic and Pseudophakic Eyes
Victor Gonzales, MD

11:26 Discussion

11:29 Effect of Doxycycline versus Placebo on Retinal Function and Diabetic Retinopathy Progression in Patients with Severe Nonproliferative or Non-High-Risk Proliferative Diabetic Retinopathy: A Randomized Trial
Ingrid Scott, MD

11:35 Discussion

11:38 Topical Nepafenac to Manage Non-central Diabetic Macular Edema
Scott Friedman, MD

11:41 Discussion

11:44 ADJOURN